| Title: |
15-year remission in refractory FLT3-mutated AML attained by sorafenib. |
| Authors: |
Rummelt, Christoph, Pfeifer, Dietmar, Wäsch, Ralph, Zeiser, Robert, Duyster, Justus, Finke, Jürgen, Lübbert, Michael |
| Source: |
Annals of Hematology; Nov2024, Vol. 103 Issue 11, p4801-4803, 3p |
| Subject Terms: |
PROTEIN-tyrosine kinase inhibitors, HEMATOPOIETIC stem cell transplantation, ACUTE myeloid leukemia, MOLECULAR genetics, SORAFENIB, BLAST injuries |
| Abstract: |
The article published in the Annals of Hematology discusses a case study of a 38-year-old patient with refractory FLT3-mutated AML who achieved a 15-year remission through sorafenib treatment combined with donor lymphocyte infusions. The patient initially presented with de novo AML and underwent HCT, but relapsed shortly after. Sorafenib treatment, followed by DLIs, led to sustained molecular remission for over 7.5 years without specific anti-leukemic therapy. The study highlights the potential of sorafenib and DLIs in inducing long-lasting remissions in FLT3-ITD mutated AML patients post-HCT, emphasizing the importance of continued FLT3 inhibition with DLIs in such cases. [Extracted from the article] |
|
Copyright of Annals of Hematology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
